Your browser doesn't support javascript.
loading
The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective.
Filippi, Luca; Urso, Luca; Ferrari, Cristina; Guglielmo, Priscilla; Evangelista, Laura.
Afiliación
  • Filippi L; Nuclear Medicine Unit, Department of Onco-hematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy.
  • Urso L; Department of Translational Medicine, University of Ferrara, Ferrara, Italy. luca.urso@unife.it.
  • Ferrari C; Nuclear Medicine Unit, Interdisciplinary Department of Medicine (DIM), University of Bari "Aldo Moro", Bari, Italy.
  • Guglielmo P; Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy.
  • Evangelista L; Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Eur J Nucl Med Mol Imaging ; 2024 Aug 07.
Article en En | MEDLINE | ID: mdl-39110196
ABSTRACT

INTRODUCTION:

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors. It predominantly affects younger women and is associated with a poor prognosis. This systematic review aims to evaluate the current role of positron emission tomography (PET) in the management of TNBC patients and to identify future research directions.

METHODS:

We systematically searched the PubMed, Scopus, and Web of Science databases up to February 2024. A team of five researchers conducted data extraction and analysis. The quality of the selected studies was assessed using a specific evaluation form.

RESULTS:

Twenty-eight studies involving 2870 TNBC patients were included in the review. Key clinical applications of PET in TNBC included predicting pathological complete response (pCR) in patients undergoing neoadjuvant chemotherapy (NAC), assessing the prognostic value of baseline PET, and initial disease staging. Two studies utilized PSMA-ligand agents, while the majority used [18F]FDG-based PET. Significant associations were found between baseline [18F]FDG uptake and molecular biomarkers such as PDL-1, androgen receptor, and Ki67. Baseline [18F]FDG PET led to the upstaging of patients from stage IIB to stage IV, influencing treatment decisions and survival outcomes. In the NAC setting, serial PET scans measuring changes in [18F]FDG uptake, indicated by maximum standardized uptake value (SUVmax), predicted pCR with varying cut-off values correlated with different response rates. Semiquantitative parameters such as metabolic tumor volume (MTV) and PET lung index were prognostic for metastatic disease.

CONCLUSIONS:

In TNBC patients, [18F]FDG PET is essential for initial disease staging in both localized and metastatic settings. It is also useful for assessing treatment response to NAC. The ability of PET to correlate metabolic activity with molecular markers and predict treatment outcomes highlights its potential in TNBC management. Further prospective studies are needed to refine these clinical indications and establish its definitive role.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania